Mankind Pharma acquires 70% stake in Armed Cell Therapeutics for EUR 48 million

Lakefront offloads CAR-T programs to Armed Cell as Mankind Pharma takes control of the Belgian startup - European Biotechnology Magazine

Lakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell Therapeutics for €8 million upfront, while India's Mankind Pharma has agreed to acquire 70% of the buyer for €48 million.

Mankind Pharma to acquire 70% stake in Armed Cell Therapeutics for EUR 48 million

The deal will give Mankind Pharma access to a pipeline of CAR-T therapies for cancer, including programmes targeting non-Hodgkin lymphoma and small cell lung cancer

Mankind Pharma acquires 70% stake in Armed Cell Therapeutics for EUR 48 million

[City, October 15, 2026]: Mankind Pharma has signed a definitive agreement to acquire a 70% stake in Belgium-based Armed Cell Therapeutics for EUR 48 million, marking its entry into the next-generation CAR-T therapy segment for cancer. The acquisition is aimed at expanding Mankind Pharma’s presence in advanced cancer therapies, the company said. Armed Cell Therapeutics […]

Mankind Pharma to Enter CAR-T Cancer Therapies with Planned Acquisition of Armed Cell Therapeutics

Open the article to view the coverage from Startup Success Stories India - News & Updates for Indian Entrepreneurs